Home Alzheimer’s Disease Use of Post-HSCT Cyclophosphamide Improves Transplantation Outcomes for AML/MDS

Use of Post-HSCT Cyclophosphamide Improves Transplantation Outcomes for AML/MDS

A study, published in Cancers, indicated that hematopoietic stem cell transplantation (HSCT) with prior use of checkpoint inhibitors appears feasible in patients with acute myeloid leukemia (AML) and/or myelodysplastic syndromes (MDS) and the use of post-HSCT cyclophosphamide (PTCy) as graft-versus host disease (GVHD) prophylaxis improves outcomes.

“Taken together, these data indicate that the use of prior checkpoint inhibitors needs to be considered within the donor/hematopoietic stem cell selection and GVHD prophylaxis plan for patients undergoing HSCT,” the authors wrote.

In this study, a retrospective analysis of 43 patients with AML and/or MDS who were treated with an antiprogrammed cell death protein 1 (PD-1) (32 patients) or anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (9 patients) blockade or both (2 patients) prior to HSCT with the primary outcome of acute…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

How has COVID-19 affected the global cancer community? – IBTA

Save the date: Coalition Connection: COVID-19 on 4 February 06:30am PST/ 09:30am EST/ 02:30pm GMT/ 03:30pm CET On 4th February 2021, the Global Cancer Coalition Network...

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

Recent Comments